Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
UBS
Fish and Richardson
Covington
Boehringer Ingelheim
Farmers Insurance
Fuji
Cerilliant
Merck

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PROMETHAZINE VC PLAIN

« Back to Dashboard

Clinical Trials for Promethazine Vc Plain

Trial ID Title Status Sponsor Phase Summary
NCT00270777 Improving Safety of Antivenom in People Bitten by Snakes Completed University of Kelaniya Phase 4 A study to increase the safety of polyvalent antivenom involving 1000 patients in three centres: low dose adrenaline, promethazine, & hydrocortisone (alone and in combination) to prevent acute adverse reactions to antivenom in people bitten by snakes: randomised, double blind, placebo-controlled trial.
NCT00429832 A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department Completed GlaxoSmithKline Phase 4 This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department.
NCT00429832 A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department Completed University of New Mexico Phase 4 This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department.
NCT00455234 Rapid Tranquillization Trial: TREC-India II Completed Christian Medical College, Vellore, India Phase 3 Three hundred consecutive adult patients presenting to the emergency services of the department of psychiatry and who are diagnosed by the treating doctor to be needing tranquillization to control agitated or aggressive behavior will be randomized to receive either Injection Olanzepine I.M. or Injection Haloperidol 10mg + Injection Promethazine 50 mg in this parallel group, block randomized, centrally-randomzed, allocation-concealed, assessor-blinded pragmatic clinical trial. The main outcome measure that the two treatments would be compared on would be the clinical state of the patient 4 hours after intervention, but the rate of tranquillization, degree of sedation, proportions tranquil and / or asleep at 15, 30, 60 and 240 minutes, need for additional medication, use of physical restraints, doctors called back, numbers absconding and adverse effects at each of these time points would also be compared. Compliance with oral medication and adverse effects at the end of 2 weeks would also be compared.
NCT00541671 Prevention of Narcotic-Induced Nausea Terminated Christiana Care Health Services N/A We are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some doctors always give medicine to prevent the possible side effect of nausea, while others do not. We are looking to see if this extra medicine is helpful in preventing nausea. The goal is to screen all patients with pain and enroll enough subjects to reach our goal of 164 evaluable study participants.
NCT00542542 Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery Completed M.D. Anderson Cancer Center Phase 3 Primary Objective: To determine whether the use of a paravertebral block in patients undergoing reconstructive surgery for breast cancer results in decreased immediate post-operative pain compared with patients having only general anesthesia. Secondary Objectives: 1. To determine whether the use of a paravertebral block in patients undergoing reconstructive surgery for breast cancer results in decreased post-operative pain in the first 24 hours after surgery compared with patients having only general anesthesia. 2. To determine whether the use of a paravertebral block in patients undergoing reconstructive surgery for breast cancer results in decreased post-operative nausea and vomiting in the first 24 hours as compared with patients having only general anesthesia. 3. To determine whether the use of a paravertebral block in patients undergoing reconstructive surgery for breast cancer results in a decreased length of hospital stay compared with patients having only general anesthesia.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Promethazine Vc Plain

Condition Name

Condition Name for Promethazine Vc Plain
Intervention Trials
Nausea 9
Pain 4
Vomiting 4
Postoperative Nausea and Vomiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Promethazine Vc Plain
Intervention Trials
Nausea 15
Vomiting 12
Postoperative Nausea and Vomiting 6
Emergencies 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Promethazine Vc Plain

Trials by Country

Trials by Country for Promethazine Vc Plain
Location Trials
United States 20
Iran, Islamic Republic of 3
Israel 2
Canada 2
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Promethazine Vc Plain
Location Trials
Pennsylvania 5
Texas 4
District of Columbia 1
Massachusetts 1
New Hampshire 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Promethazine Vc Plain

Clinical Trial Phase

Clinical Trial Phase for Promethazine Vc Plain
Clinical Trial Phase Trials
Phase 4 10
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Promethazine Vc Plain
Clinical Trial Phase Trials
Completed 20
Recruiting 6
Unknown status 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Promethazine Vc Plain

Sponsor Name

Sponsor Name for Promethazine Vc Plain
Sponsor Trials
Charleston Laboratories, Inc 4
M.D. Anderson Cancer Center 2
Merck Sharp & Dohme Corp. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Promethazine Vc Plain
Sponsor Trials
Other 36
Industry 11
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Dow
Cipla
Colorcon
US Department of Justice
Argus Health
McKinsey
Fuji
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.